Zimura showed positive results at 18 months in a phase 3 clinical trial in patients with geographic atrophy secondary to age-related macular degeneration, according to a press release from Iveric bio.
The 18-month results of Zimura (avacincaptad pegol), a novel complement C5 inhibitor, support the positive 12-month results, in which Zimura met the specified primary endpoint with statistical significance, the release said.
In the Zimura 2 mg group, the reduction in the mean rate of geographic atrophy growth was 28.11% at 18 months compared with the sham control group (P (Read more...)
Uncategorized